Tvardi Therapeutics
TVRD
144 hedge funds and large institutions have $558M invested in Tvardi Therapeutics in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 15 closing their positions.
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
14% more funds holding
Funds holding: 126 → 144 (+18)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more ownership
Funds ownership: 1.82% → 1.82% (+0%)
0% less capital invested
Capital invested by funds: $559M → $558M (-$576K)
23% less call options, than puts
Call options by funds: $8.31M | Put options by funds: $10.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.4M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27.7M |
| 3 |
BlackRock
New York
|
+$15.8M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.7M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.43M |
| 4 |
CG
Carmignac Gestion
Paris,
France
|
-$6.42M |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$5.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
151
Aperio Group
Sausalito,
California
| – | -$88K | -114 | Closed |
|
152
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$54K | -69 | Closed |
|
|
TA
153
TCG Advisors
Austin,
Texas
| – | -$33K | -42 | Closed |
|
|
JG
154
Jefferies Group
New York
| – | -$4K | -6 | Closed |
|
|
CFGS
155
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2.49K | -3 | Closed |
|
|
WCM
156
Whitener Capital Management
Rocky Mount,
North Carolina
| – | -$2K | -3 | Closed |
|
|
GI
157
Gradient Investments
Arden Hills,
Minnesota
| – | -$2K | -2 | Closed |
|
|
RFM
158
Royal Fund Management
Lady Lake,
Florida
| – | +$831 | +1 | New |
|
|
TFS
159
TrustCore Financial Services
Brentwood,
Tennessee
| – | +$831 | +1 | New |
|
TVRD Hedge Fund Activity: Q3 2019 in Review
144 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2019, worth a combined $558M — down 0.1% from $559M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TVRD positions and 15 closed out — a net gain of 18 holders — while 49 added to existing stakes and 35 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $42.4M. The largest seller was State Street, cutting an estimated $21M.
- 144 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2019, up from 126 in Q2 2019.
- Funds reported $558M of Tvardi Therapeutics stock for Q3 2019, down 0.1% quarter-over-quarter.
- 33 funds opened new Tvardi Therapeutics positions in Q3 2019 and 15 closed out, a net change of +18 holders.
- The largest Tvardi Therapeutics buyer in Q3 2019 was T. Rowe Price Associates, an estimated $42.4M added.
- The largest Tvardi Therapeutics seller in Q3 2019 was State Street, an estimated $21M sold.
Based on aggregated 13F filings for Q3 2019.